SRPT240726P119000
- 18.00
- 0.000.00%
Sarepta Therapeutics Newsroom
Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 38.04%: Here's Is How to Trade
Here's How Much $1000 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today
Sarepta Therapeutics (NASDAQ:SRPT) has outperformed the market over the past 10 years by 10.36% on an annualized basis producing an average annual return of 21.14%. Currently, Sarepta Therapeutics
Buy Rating Affirmed for Sarepta Therapeutics Amid Strong Elevidys Demand and Strategic Growth Outlook
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
On CNBC's "Mad Money Lightning Round," Jim Cramer said Fortinet, Inc. (NASDAQ:FTNT) is not his favorite. He added that we own Palo Alto Networks, Inc. (NASDAQ:PANW) for the charitable trust.On July 11
Express News | Cassava Sciences Inc: Renewal of Quarterly Analyst Calls
Express News | Cassava Sciences Inc: Ongoing Phase 3 Trials Are Being Run According to FDA and Industry Standards
Express News | Cassava Sciences Inc: Is Reviewing Its Disclosure Practices to Ensure It Is Providing Stakeholders With Clear and Comprehensive Information
Express News | Cassava Sciences Inc: Co and Burns Agreed That She Step Down From Her Role, Effective Immediately
Express News | Cassava Sciences Inc: Lindsay Burns Is Also Leaving Employ of Company
Express News | Cassava Sciences Inc: Initiates Search for a New CEO
Express News | Cassava Sciences Inc -Remi Barbier Resigns as President and CEO and From Board of Directors
Express News | Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
Solid Biosciences up 10% Following J.P. Morgan Upgrade
Sarepta Therapeutics (NASDAQ:SRPT) Shareholders Have Earned a 31% CAGR Over the Last Three Years
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But if you buy shares in a really great company, you can more than
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
After a Big Win, Is Sarepta Therapeutics Stock a Buy?
Here's How Much $100 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today
Sarepta Therapeutics (NASDAQ:SRPT) has outperformed the market over the past 10 years by 8.61% on an annualized basis producing an average annual return of 19.45%. Currently, Sarepta Therapeutics has
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
Expert Outlook: Sarepta Therapeutics Through The Eyes Of 25 Analysts
Ratings for Sarepta Therapeutics (NASDAQ:SRPT) were provided by 25 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The table below provides a snapshot of their
Piper Sandler Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $205
Piper Sandler analyst Biren Amin maintains $Sarepta Therapeutics(SRPT.US)$ with a buy rating, and maintains the target price at $205.According to TipRanks data, the analyst has a success rate of 42.1%